Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 4/20 | 0.49 |
| ▸ | THRA | P10827 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.45 |
| ▸ | FAAH | O00519 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | SOAT1 | P35610 | 7/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3202798 | 1.00 | THRB (0.49) | THRBTHRAALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL9321240 | 1.00 | THRB (0.49) | THRBTHRAALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL3190130 | 1.00 | THRB (0.49) | THRBTHRAALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL3183775 | 1.00 | THRB (0.49) | THRBTHRAALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL11487812 | 1.00 | THRB (0.49) | THRBTHRAALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL3201268 | 1.00 | THRB (0.49) | THRBTHRAALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL3201840 | 1.00 | THRB (0.49) | THRBTHRAALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL3191168 | 1.00 | THRB (0.49) | THRBTHRAALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL3198273 | 0.98 | ALDH1A1 (0.47) | THRBTHRAALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL3196071 | 0.92 | ALDH1A1 (0.48) | THRBTHRAALDH1A1CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7678907-B2 | Halogenation of rylen-carboximides with elementary halogen in a two-phase mixture comprising an organic solvent and water, wherein formed halogen hydroxide is continuously removable from the organic solvent | BASF AKTIENGESSELLSCHAFT (DE) | 2010-03-16 | — | — | US | disclosed |
| EP-1802622-B1 | HALOGENATION OF RYLEN-CARBOXIMIDES WITH ELEMENTARY HALOGEN IN A TWO-PHASE MIXTURE COMPRISING AN ORGANIC SOLVENT AND WATER, WHEREIN FORMED HALOGEN HYDROCIDE IS CONTINUOUSLY REMOVABLE FROM THE ORGANIC SOLVENT | BASF SE (DE) | 2008-04-23 | — | — | EP | disclosed |
| US-20080058526-A1 | Halogenation of Rylen-Carboximides with Elementary Halogene in a Two-Phase Mixture Comprising an Organic Solvent and Water, Wherein Formed Halogene Hydrocide is Continously Removable from the Organic Solvent | BASF AKTIENGESELLSCHAFT (DE) | 2008-03-06 | — | — | US | disclosed |
| EP-1802622-A1 | HALOGENATION OF RYLEN-CARBOXIMIDES WITH ELEMENTARY HALOGEN IN A TWO-PHASE MIXTURE COMPRISING AN ORGANIC SOLVENT AND WATER, WHEREIN FORMED HALOGEN HYDROCIDE IS CONTINUOUSLY REMOVABLE FROM THE ORGANIC SOLVENT | BASF AKTIENGESELLSCHAFT (DE) | 2007-07-04 | — | — | EP | disclosed |
| WO-2006037539-A1 | HALOGENATION OF RYLEN-CARBOXIMIDES WITH ELEMENTARY HALOGEN IN A TWO-PHASE MIXTURE COMPRISING AN ORGANIC SOLVENT AND WATER, WHEREIN FORMED HALOGEN HYDROCIDE IS CONTINUOUSLY REMOVABLE FROM THE ORGANIC SOLVENT | BASF AKTIENGESELLSCHAFT (DE) | 2006-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058526-A1 | Halogenation of Rylen-Carboximides with Elementary Halogene in a Two-Phase Mixture Comprising an Organic Solvent and Water, Wherein Formed Halogene Hydrocide is Continously Removable from the Organic Solvent | CYP8B1, HACL2, CTRB2 | THRB 323/4885THRA 270/4885ALDH1A1 1379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.